Effect of drug-eluting bead DACE combined with systemic treatment for hepatocellular carcinoma in different locations
10.13929/j.issn.1672-8475.2025.04.002
- VernacularTitle:载药微球TACE联合系统治疗用于不同位置肝细胞癌效果
- Author:
Xingli YAN
1
;
Zhen LI
;
Jie LI
;
Luqi HU
;
Yifan LI
;
Yanan ZHAO
;
Yuyuan ZHANG
;
Junying LIU
;
Pengchao ZHAN
;
Xin LI
;
Peijie LYU
;
Yancang ZHANG
Author Information
1. 郑州大学第一附属医院放射介入科 河南省肿瘤微创介入工程技术研究中心 郑州市肿瘤介入诊疗技术创新与转化重点实验室,河南郑州 450052
- Publication Type:Journal Article
- Keywords:
carcinoma,hepatocellular;
anatomy;
chemoembolization,therapeutic
- From:
Chinese Journal of Interventional Imaging and Therapy
2025;22(4):238-242
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of drug-eluting bead DACE(DEB-TACE)combined with systemic treatment for hepatocellular carcinoma(HCC)in different locations.Methods A total of 204 HCC patients who underwent DEB-TACE combined with systemic therapy(targeted and immunotherapy)were retrospectively collected.According to the anatomical location of HCC,86 cases with lesions located at the main trunk of portal vein(PV)or within 1 cm of the first PV branch were classified into central type group,while 118 cases with lesions located at the other areas were classified as peripheral type group.Follow-up was regularly performed after DEB-TACE until August,2024.The objective response rate(ORR)and disease control rate(DCR)at 1,3,6 and 12 months after DEB-TACE,also patients'progression-free survival(PFS)and overall survival(OS)were compared between groups.Results All patients were followed up for a median of 32.6 months,during which 164 cases died.Significant differences of ORR at 1 and 3 months after DEB-TACE(77.91％[67/86]vs.89.83％[106/118],34.88％[30/86]vs.54.24％[64/118])and DCR at 3 and 6 months after DEB-TACE(51.16％[44/86]vs.66.95％[79/118],34.88％[30/86]vs.50.00％[59/118])were found between groups(all P＜0.05).Patients'PFS(30.18[9.12,48.54]months)and OS(37.36[17.79,56.68])in peripheral type group were better than those in central type group(20.11[11.35,28.87]months and 23.24[3.11,43.47]months,x2=3.971,4.162,P=0.048,0.041).Conclusion The effect of DEB-TACE combined with systemic treatment for peripheral type HCC was better than for central type HCC.
